HHD Pharm
Yes
Non-Customized
Adult
>98%
White
Pharmaceutical Grade
hhdpharm
Alumininum Foli Bags
10g, 50g, 200g, 1kg, 5kg
China
Product Description
Wuhan HHD Supply Regorafenib Anticancer Inhibitor Raw Material Regorafenib Powder CAS 755037-03-7
Basic information:
| Prodcut name | Regorafenib |
| Synonyms | 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide;4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;Stivarga®;4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; |
| MOQ | 10g |
| CAS | 755037-03-7 |
| Appearance | Powder |
| Molecular Formula | C21H15ClF4N4O3 |
| Molecular Weight | 482.815 |
| Assay | 99% |
| Application | Pharma grade |
| Packing | As per your request |
| Storage | Preserve in tight, light-resistant containers in a cool place |
Description:
Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types.[1] By 2015 it had 2 US approvals for advanced cancers.
